-

Food Processing Plant Sees Huge Reduction in Employee COVID-19 Rates After Using Ondine Biomedical’s Nasal Photodisinfection

VANCOUVER, Canada--(BUSINESS WIRE)--Research presented at the PDT-PDD Conference in Nancy, France showed that a large food processing plant in Manitoba, Canada, was able to reduce the rate of COVID-19 amongst its employees following the use of Ondine Biomedical’s nasal photodisinfection. The rate of COVID-19 positive tests in the workforce fell from 6.4% to 0.5%, a reduction of over 10 times (p<0.0001) compared to rates in the community. The reduction in COVID-19 cases at the plant meant that food production was able to continue without disruption at a crucial time during the COVID-19 pandemic.

Between July 2020 and August 2021, approximately 1,500 employees were nasally photodisinfected on a voluntary basis during paid work hours. Compliance with the treatment was extremely high at 85% by the end of the study period. During the study, employees used Steriwave™ nasal photodisinfection to eliminate bacteria, fungi and viruses, including SARS-CoV-2, from their noses. The nose has been shown to be the primary infection site for many infectious diseases, and eliminating pathogens from the nose has been demonstrated to reduce disease progression.i

Steriwave works to eliminate nasal bacteria, viruses and fungi with a simple, 5-minute treatment. The two-step process involves the application of a light-activated agent to each nostril using a nasal swab, followed by illumination of the area with a specific wavelength of laser light. The light activates the photodynamic agent, causing an oxidative burst that destroys all types of pathogens.

Dr. Nicolas Loebel, President and Chief Technology officer of Ondine Biomedical Inc., said: “These results were provided to us by the local infection control team in Manitoba. Facilities like this plant are highly vulnerable to disease outbreaks, significantly disrupting food production and impacting sales. When nasal photodisinfection was added to the standard infection control bundle, COVID-19 rates were suppressed by over 10 times compared to the surrounding community rates.”

About Ondine Biomedical Inc.

Ondine Biomedical Inc. is a Canadian headquartered company innovating in the field of photodisinfection therapies. Ondine has a pipeline of investigational products, based on its proprietary photodisinfection platform, in various stages of development. Products beyond nasal photodisinfection include therapies for a variety of medical indications such as sinusitis, ventilator-associated pneumonia, burns, and other indications.

i https://www.nature.com/articles/s41598-022-18513-0.pdf

Contacts

Media Contact
Simon Vane Percy, Amanda Bernard
+44 (0) 77 1000 5910
amanda@vanepercy.com

Ondine Biomedical Inc.

LSE:OBI

Release Summary
New research suggests that nasal photodisinfection could significantly reduce employee COVID-19 positive rates at food processing facilities.
Release Versions

Contacts

Media Contact
Simon Vane Percy, Amanda Bernard
+44 (0) 77 1000 5910
amanda@vanepercy.com

More News From Ondine Biomedical Inc.

Ondine Biomedical's US $11M Fundraise Enables a Q4 2024 Start of Its Pivotal Phase 3 US Trial

VANCOUVER, British Columbia--(BUSINESS WIRE)--Ondine Biomedical announces that it is accelerating its US Phase 3 trial following its recent successful raise of Cdn $16 million (£9m, US $11m)....

Ondine Successfully Raised C$4.91 Million to Support Acceleration of Its Commercial Rollout of Nasal Decolonization to Prevent Healthcare-associated Infections

VANCOUVER, Canada--(BUSINESS WIRE)--Following its successful fundraising of C$4.91 million (US$3.62), Canadian life sciences company Ondine Biomedical Inc. will continue accelerating commercialisation of its proven nasal photodisinfection technology. This cutting-edge technology replaces topical antibiotics for the prevention of healthcare-associated infections (HAIs) and kills all types of pathogens – bacteria, viruses and fungi – without causing antimicrobial resistance. The company has confi...

Ondine Biomedical’s photodisinfection recommended as standard of care

VANCOUVER, British Columbia--(BUSINESS WIRE)--Canadian life sciences company, Ondine Biomedical Inc., reports that an independent, peer-reviewed research paper, “Effectiveness of prophylactic intranasal photodynamic disinfection therapy and chlorhexidine gluconate body wipes for surgical site infection prophylaxis in adult spine surgery” from Vancouver General Hospital (“VGH”) has been published in the Canadian Journal of Surgery. The study spanned an eight-year period and involved 13,493 patie...
Back to Newsroom